Avadel Pharmaceuticals Stock Predictions

Healthcare > Drug Manufacturers - Specialty & Generic

Buy AVDL

*Your capital is at risk

$21.64

+0 (+0%)

At Close: May 08, 2026

Currently predicting for Thu, 6 Aug 2026

AVDL Live board

Community Bull/Bear

Target Next close

Join the AVDL prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

AVDL Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For AVDL

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

AVDL Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT AVADEL PHARMACEUTICALS PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorpo...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
N NXDR $2.27	7.93%	Aug 03
MC $67.08	3.53%	Jul 31
FCX $62.63	10.79%	Jul 31
ARW $212.85	6.58%	Jul 30
BIIB $202.19	2.20%	Jul 24

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by